WO2006000923A3 - Macrolide compositions as therapeutic agent - Google Patents

Macrolide compositions as therapeutic agent Download PDF

Info

Publication number
WO2006000923A3
WO2006000923A3 PCT/IB2005/002899 IB2005002899W WO2006000923A3 WO 2006000923 A3 WO2006000923 A3 WO 2006000923A3 IB 2005002899 W IB2005002899 W IB 2005002899W WO 2006000923 A3 WO2006000923 A3 WO 2006000923A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
compositions
macrolide compositions
macrolide
treatment
Prior art date
Application number
PCT/IB2005/002899
Other languages
French (fr)
Other versions
WO2006000923A2 (en
Inventor
Nicolas Fischer
Bernard Mach
Krzysztof Masternak
Tony Buss
Mui Mui Sim
Original Assignee
Novimmune Sa
Merlion Pharmaceuticals Pte Lt
Nicolas Fischer
Bernard Mach
Krzysztof Masternak
Tony Buss
Mui Mui Sim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa, Merlion Pharmaceuticals Pte Lt, Nicolas Fischer, Bernard Mach, Krzysztof Masternak, Tony Buss, Mui Mui Sim filed Critical Novimmune Sa
Publication of WO2006000923A2 publication Critical patent/WO2006000923A2/en
Publication of WO2006000923A3 publication Critical patent/WO2006000923A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides compositions including a macrolide compound that inhibits MHC class II expression. The compositions of the invention are used as an immunosuppressive agent in the treatment prior to, during and/or after organ or tissue transplantation, as well as in the treatment of immune-related disorders.
PCT/IB2005/002899 2004-06-03 2005-06-03 Macrolide compositions as therapeutic agent WO2006000923A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57701104P 2004-06-03 2004-06-03
US60/577,011 2004-06-03

Publications (2)

Publication Number Publication Date
WO2006000923A2 WO2006000923A2 (en) 2006-01-05
WO2006000923A3 true WO2006000923A3 (en) 2006-12-28

Family

ID=35782166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002899 WO2006000923A2 (en) 2004-06-03 2005-06-03 Macrolide compositions as therapeutic agent

Country Status (1)

Country Link
WO (1) WO2006000923A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007110704A2 (en) * 2005-09-28 2007-10-04 Novimmune Sa Macrolide compositions as therapeutic agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075126A1 (en) * 1999-06-03 2000-12-14 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mycolactone and related compounds, compositions and methods of use
WO2004087673A2 (en) * 2003-03-28 2004-10-14 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075126A1 (en) * 1999-06-03 2000-12-14 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mycolactone and related compounds, compositions and methods of use
WO2004087673A2 (en) * 2003-03-28 2004-10-14 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"IMMUNOSUPPRESSIVE PROPERTIES OF THE SOLUBLE TOXIN FROM MYCOBACTERIUM ULCERANS", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 157, no. 3, March 1988 (1988-03-01), pages 577 - 580, XP000918626, ISSN: 0022-1899 *
ALI A PAHLEVAN ET AL: "The Inhibitory Action of Mycobacterium ulcerans Soluble Factor on Monocyte/T-Cell Cytokine Production and NF-kB Function", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 163, no. 7, 1 October 1999 (1999-10-01), pages 3928 - 3935, XP002148652, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2006000923A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2006004910A3 (en) Improved bispecific antibodies
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
ZA201201391B (en) Methods, compositions, and kits for the treatment of medical conditions
WO2004110390A3 (en) Anti-cd74 immunoconjugates and methods
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2006020773A3 (en) Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
MY143795A (en) Tetrahydropyridoindole derivatives
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2004101758A3 (en) Composition for maintaining organ and cell viability
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
EP2260835A3 (en) Composition for proteasome inhibition
EP2450360A3 (en) (S)-N-Methylnaltrexone
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
UA88463C2 (en) Pharmaceutical composition comprising compound i and method of treating hiv infection
WO2006003492A3 (en) Compositions and methods for treating pathological infections
EP2192901A4 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2008003028A3 (en) Pharmaceutical compositions comprising droxidopa
WO2006086693A3 (en) Medical devices
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
TW200716088A (en) Formulations and methods for treating amyloidosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase